Cell Models of Castration Resistant and High Dose Testosterone-Resistant Prostate Cancer Recapitulate the Heterogeneity of Response Observed in Clinical Practice
Authors:
- Laura S. GrahamLGLaura S. Graham
- Lih-Jen SuLSLih-Jen Su
- Andrew NicklawskyANAndrew Nicklawsky
- Frances Xiuyan FengFFFrances Xiuyan Feng
- David OrlickyDODavid Orlicky
- Joseph PetraccioneJPJoseph Petraccione
- Maren Salzmann-SullivanMSMaren Salzmann-Sullivan
- Steven K. NordeenSNSteven K. Nordeen
- Thomas W. FlaigTFThomas W. Flaig
Open Access
Abstract
The use of supraphysiologic testosterone, particularly when alternated with an anti-androgen agent in men with metastatic castration-resistant prostate cancer (CRPC), has demonstrated promising results in clinical trials. As the use of this therapy in clinical practice is more widely adopted, there will be a growing need to understand the mechanisms of resistance. To that end, we independently derived three separate cell models of testosterone-sensitive CRPC. From each CRPC line, high dose testosterone-resistance (HTR) lines were selected. We demonstrated the differential response of the three CRPC lines to a high dose of testosterone in vitro and in vivo. We subsequently demonstrated the resistance of the HTR lines to testosterone and varying responses to testosterone withdrawal in vivo. The heterogeneity in responses to hormonal manipulation is correlated with varying levels of androgen receptor expression within the population. Overall, we show that we have developed three models of HTR that can be used to study the mechanisms of high dose testosterone resistance and identify potential therapeutic targets.Keywords
Funding Information
- Office of the Assistant Secretary of Defense for Health Affairs through the Congressionally Directed Medical Research Program under Award (DOD W81XWH-20-1-0853, K12CA086913, P30CA046934)
- LG (DOD W81XWH-20-1-0853, K12CA086913, P30CA046934)
- University of Colorado Cancer Center Support Grant (DOD W81XWH-20-1-0853, K12CA086913, P30CA046934)
This publication has 29 references indexed in Scilit:
- Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment OutcomesJAMA Oncology, 2024
- A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsEuropean Urology, 2021
- Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF SignalingCancer Cell, 2017
- Neuronal Trans‐Differentiation in Prostate Cancer CellsThe Prostate, 2016
- Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN StudyThe Prostate, 2016
- Targeting persistent androgen receptor signaling in castration-resistant prostate cancerMedical Oncology, 2016
- Of mice and men‐warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectivelyThe Prostate, 2013
- Adaptive auto‐regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancerThe Prostate, 2012
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancerThe Prostate, 2010